Clinical significance of multigene assay in papillary thyroid carcinoma / 临床耳鼻咽喉头颈外科杂志
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
; (12): 375-379, 2023.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-982752
Responsible library:
WPRO
ABSTRACT
Objective:
To analyze the clinical significance of multigene assay in papillary thyroid carcinoma(PTC).Methods:
Patients who underwent thyroidectomy in a tertiary hospital from August 2021 to May 2022 were enrolled. The eight-gene panel was used to detect the tumor tissue of patients, and the correlation between gene mutations and clinical features was analyzed.Results:
Among 161 patients, mutation rate of BRAF V600E, RET/PTC1 and TERT promotor were 82.0%, 6.8% and 4.3%, respectively. BRAF V600E mutation was more common in male patients(P=0.023). TERT promotor-mutated tumors had a large diameter(P=0.019), a high proportion of multifocal lesions(P=0.050), and a large number of lymph node metastases(P=0.031). Among 89 patients who completed preoperative BRAF detection, there was a strong consistency between the preoperative aspiration test and postoperative panel(Cohen κ=0.694, 95%CI 0.482-0.906, P<0.01). In the hematoxylin-eosin sections obtained from 80 patients, BRAF V600E was still the main type of gene mutation, and the classical/follicular type was more distributed. TERT promotor and RET/PTC1 mutation were the main genetic events for tall-cell/columnar/hobnail type and diffuse sclerosing type, respectively. One-way ANOVA showed that there were differences in diagnosis age(P=0.029) and tumor size(P<0.01) among different pathological types.Conclusion:
As a simple and feasible clinical detection method for PTC, the multigene assay can supplement the identification of important genetic events other than BRAF V600E, and provide more prognostic information and follow-up hints for postoperative patients.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Thyroid Neoplasms
/
Carcinoma, Papillary
/
Proto-Oncogene Proteins B-raf
/
Thyroid Cancer, Papillary
/
Clinical Relevance
/
Mutation
Limits:
Humans
/
Male
Language:
Chinese
Journal:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
Year:
2023
Document type:
Article